Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2024-11-09 M&A Activity
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
M&A Activity 2024
M&A Activity Classification · 99% confidence The document text is a press release announcing a strategic license agreement between ALK and ARS Pharmaceuticals regarding the drug neffy®. It details financial considerations (upfront payment, milestones, royalties), strategic rationale, and future plans. Crucially, the document ends with an 'Attachment' section listing a file named 'FM_18_24UK_09112024-final' and includes contact information for Investor Relations, indicating it is an official corporate announcement intended for the market. This type of announcement, detailing a significant business transaction (licensing/partnership) and financial impact, is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the focus was purely on the cash outlay/debt structure. However, since it is a broad business development announcement that doesn't fit the specific definitions for ER, IR, 10-K, or DIV, and it is not explicitly a proxy statement (DEF 14A) or a management discussion (MDA), the most appropriate general category for significant, non-standard corporate news released via a wire service is RNS. Given the content is a major business deal announcement, it is a formal regulatory disclosure, fitting the RNS fallback category best, although it shares characteristics with CAP. I will classify it as RNS as it is a general regulatory announcement via a wire service.
2024-11-09 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a press release announcing a strategic licensing agreement between ALK and ARS Pharmaceuticals regarding the drug neffy®. It details financial terms (upfront payment, milestones, royalties), strategic implications for ALK's growth, and future launch plans. The text concludes with contact information, a note about an upcoming conference call, and an attachment link. This structure—a formal announcement of a significant business event (licensing deal) that impacts future financial performance and strategy—is characteristic of a general corporate announcement. Since it is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER), or a proxy statement (DEF 14A), and it is not merely announcing the publication of another report (RPA), the most appropriate classification is a general Regulatory Filing (RNS), which serves as the catch-all for significant, non-standard corporate disclosures, especially those distributed via news wire services like this one appears to be.
2024-11-09 Danish
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a press release from ALK announcing a strategic licensing agreement with ARS Pharmaceuticals for the drug *neffy®*. It details the financial terms (upfront payment, milestones, royalties), market potential, and strategic fit with ALK's 'Allergy+' strategy. This type of announcement, which details a significant corporate transaction (licensing/M&A activity) and its financial implications, is best classified as a general corporate announcement. Since there is no specific category for 'Licensing Agreement' or 'Corporate Transaction', and it is not a formal regulatory filing like a 10-K, ER, or IR, it falls under the general regulatory/corporate announcement category, RNS (Regulatory News Service), which serves as a fallback for significant, non-standard corporate disclosures. The document is substantial (over 10,000 characters) and contains the full details, so it is not an RPA.
2024-11-09 Danish
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a press release written in Danish announcing a strategic licensing agreement between ALK and ARS Pharmaceuticals regarding the drug neffy®. It details financial considerations (upfront payment, milestones, royalties), strategic implications for ALK's growth, and future launch plans. Crucially, the document ends with a section titled "Vedhæftet fil" (Attached file) and a link to a file named "FM_18_24DK_09112024-final". This structure—a brief announcement summarizing key news and pointing to an attached document—strongly suggests this is an announcement about the release of information rather than the full, detailed report itself. Since the content is a significant corporate announcement (licensing deal, financial impact, strategy update) that is not a standard regulatory form like 10-K or a quarterly report (IR), and it explicitly announces the publication of related material, the most appropriate classification is Report Publication Announcement (RPA). If it were a full, detailed report, it would likely be classified as MDA (Management Reports) or potentially IR (Interim Report) if it contained period financials, but here it is clearly an announcement of a transaction/event.
2024-11-09 Danish
Regulatory Filings 2024
Regulatory Filings Classification · 90% confidence The document is a press release announcing a strategic license agreement between ALK and ARS Pharmaceuticals regarding the drug neffy®. It details financial considerations (upfront payment, milestones, royalties), strategic alignment with ALK's 'Allergy+' strategy, and future launch plans. It is not a full annual report (10-K), an interim report (IR), or a formal earnings release (ER) which typically contains structured financial tables for a period. It is a specific corporate action announcement. Since it details a significant business transaction (licensing/M&A activity) and is structured as a news release, it fits best under the general category for corporate announcements that aren't strictly financial statements or management discussions. However, given the focus on a major licensing deal involving future revenue potential and payments, it strongly relates to corporate financing/capital structure changes or M&A activity. Since the definition for M&A Activity (TAR) covers 'merger proposals or takeover bids,' and this is a licensing deal which is a form of strategic transaction, TAR is a strong candidate. Alternatively, since it involves significant financial terms and future revenue streams, it could be seen as a Capital/Financing Update (CAP). Given the nature of licensing intellectual property rights, 'TAR' (Transaction/Merger/Acquisition Activity) is often used broadly for major strategic deals. However, looking at the definitions, 'CAP' covers 'Updates on company fundraising, financing activities, or capital structure changes.' A major licensing deal with upfront payments and milestones is a significant financing/transaction activity. Since it is a detailed announcement of a transaction rather than just a brief notice, it is more substantial than a general RNS. I will classify this as a major transaction announcement, which aligns closely with TAR (M&A Activity) or CAP (Financing Update). Given the context of licensing rights, TAR seems slightly more appropriate for a major strategic deal, but since it's not a merger/takeover, CAP might be safer as it involves significant financial commitments. Let's re-evaluate: This is primarily an announcement of a strategic partnership and IP licensing, not fundraising or capital structure change in the traditional sense (like issuing new stock or debt). Therefore, it is a significant corporate event announcement. Since there isn't a specific 'Strategic Partnership' code, and it's not a standard financial report, it falls between TAR and RNS. Given the detailed financial terms and strategic importance, it is more specific than RNS. I will lean towards TAR as the closest fit for a major strategic transaction, even if it's not a full M&A. If TAR is strictly M&A, then RNS is the fallback. Let's check the document length (12,703 chars) - it is substantial, so it is the report itself, not an RPA. I will classify it as RNS as it is a general corporate announcement that doesn't fit the specific financial report codes (10-K, IR, ER) or the specific transaction codes (CAP, TAR).
2024-11-09 English
Director's Dealing 2024
Director's Dealing Classification · 98% confidence The document text is in Danish and translates to 'Reporting of management transactions with ALK-Abelló A/S' B-shares and related securities'. It explicitly references Article 19 of the EU Market Abuse Regulation (MAR), which mandates the disclosure of transactions by persons discharging managerial responsibilities (PDMRs). This directly corresponds to insider trading or director's dealing reports. The filing type 'DIRS' (Director's Dealing) is the most appropriate classification. The document is short and points to an attached file, but the content itself is the required disclosure notification, not just an announcement of a report's publication, making DIRS more specific than RPA or RNS.
2024-08-27 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.